Richard Pestell was six when he first faced the devastating consequences of cancer. His best friend died from the disease and then he watched both his parents die from it, so it’s no surprise he has devoted his medical career to that field.
“It’s not about getting mad but getting even,” he said.
New Article on ProstaGene in the Philadelphia Business Journal from Senior Reporter John George:
A Montgomery County biotechnology company has raised $400,000 from private investors.
ProstaGene, which is based at the Lankenau Institute for Medical Research in Wynnewood, Pa., has developed a gene-based technology to help guide treatment decisions for patients with a type of cancer where immediate treatment is not always recommended.
ProstaGene is developing gene-based technology to diagnose and treat prostate cancer.
“A Montgomery County biotechnology startup attempting to commercialize cancer-fighting technology, developed by its founder at the Sidney Kimmel Cancer Center at Thomas Jefferson University, has raised $825,000 in a private stock sale.”
> Continue reading at the Philadelphia Business Journal